My sense is that the only thing that matters is cor's ability in the short term is to avoid going broke. In light of that, my sense is there is only one deal that matters: RD. The other indications need POC or phase 2 data, and those data aren't even in the can yet, so the earliest those indications could contribute to cor's bottom line is near the end of '09. Cor doesn't have the money to stay afloat until then, and I'm not cvonvinced a financing is realistic.
If RD is the one deal that has to get done, the candidate companies include:
Endo, Cephalon, and Purdue, Reckitt Benckiser, Baxter,...??.
One thing you mentioned in the fall is that as due dilligence nears completion, news of an impending deal tends to leak out. Obviously, based on share-price, such leakage isn't happening. Can we infer from this that a deal is months rather than weeks away?
My intention here is not to jump to conclusions one way or another, but to figure out what can be gleaned from the hue of the darkness and the depth of the silence that surrounds cor's purported negotiations.
Market Data 
Markets 
AI
